PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Prev Res (Phila). Author manuscript; available in PMC 2010 September 1.
Published in final edited form as:
PMCID: PMC2819381
NIHMSID: NIHMS173430

Chemoprevention of mouse intestinal tumorigenesis by the CDK inhibitor SNS-032

Abstract

Despite advances in screening and treatment, colorectal cancer (CRC) remains the second leading cause of cancer-related death in the United States. Cyclin-dependent kinases (Cdks) are deregulated in CRC by silencing of the Cdk inhibitor p16Ink4a and other mechanisms. We tested whether the small molecule Cdk inhibitor SNS-032 (formerly BMS-387032), which targets Cdks 2, 7, and 9, can prevent intestinal tumorigenesis in mouse models. We generated mice with high intestinal tumor loads by combining the Min (Multiple intestinal neoplasia) mutation with Ink4a/Arf mutations and inducing colitis with dextran sulfate sodium (DSS). p16-null Min mice (N = 17) began DSS treatment at week 5 and intraperitoneal injection of carrier or SNS-032 at week 6. Mice were sacrificed at week 12. SNS-032 was well tolerated and reduced colon tumor burden to 36% of that in carrier-treated mice (P < 0.001). We then extended the study to Ink4/Arf-null Min mice (N = 14) and increased the drug dose frequency. SNS-032 treatment reduced the intestinal tumor number to 25% and intestinal tumor burden to 16% of carrier-treated mice (P < 0.0001). DNA synthesis in non-neoplastic and tumor epithelial cells, detected by bromodeoxyuridine incorporation, was modestly reduced by acute SNS-032 treatment. The mitotic index, detected by histone H3 phosphorylation, was distinctly decreased (P < 0.03), and apoptosis, detected by caspase 3 activation, was increased (P < 0.005). These results demonstrate chemoprevention of intestinal tumorigenesis by SNS-032. Our findings support further study of Cdk inhibitors for chemoprevention and therapy of colon cancer.

Keywords: Cdk, colon cancer, Min, chemoprevention, Cdk inhibitor

Introduction

Despite advances in screening and treatment, colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States. Patients with inherited predispositions, chronic ulcerative colitis (UC), or a personal history of colon tumors are at particular high risk. Chemoprevention constitutes an appealing alternative method to combat the disease in such patients. Most chemoprevention has targeted inflammatory mediators (13). Among other molecular pathways that are deregulated in CRC are the Cyclin-dependent kinases (Cdks), enzymes that promote cell cycle progression and transcription of genes involved in cell replication and survival. The Cdk inhibitor p16Ink4a is frequently inactivated in sporadic and UC-associated neoplasia (47). Several small molecule Cdk inhibitors have been developed for cancer therapy and are undergoing clinical investigation (8, 9).

Although Cdk inhibitors have been studied for activity against human CRC cell lines in mouse xenograft studies (10), no studies to our knowledge have tested their efficacy in treating intestinal tumors arising in situ. Xenograft studies have the advantage of assessing drug efficacy against human CRC cells but carry the drawbacks of using immunocompromised mice and tumor growth in an artificial setting, typically a pocket of subcutaneous tissue formed by needle injection. We focused our studies on the potential of a newer inhibitor, SNS-032 (11, 12), to suppress intestinal tumorigenesis in a pre-clinical model. Thus, these studies have advantages of using immunocompetent hosts, avoiding idiosyncrasies of established cell lines, examining tumor growth in native contexts, and allowing drug access via native vasculature. Furthermore, specific pre-malignant states and genotypes can be assessed that mimic those found in human populations. Thus, studies of drug effect on tumorigenesis in situ can have valuable implications for both therapy and chemoprevention.

Materials and Methods

Animals

Min mice in a C57/B16 background were purchased from Jackson Laboratories (Bar Harbor, ME). p16-null mice (13), initially in a mixed 129Sv/FVB/C57B16 genetic background (at least 50% C57B1/6), were repeatedly backcrossed with C57/B16 mice over at least 10 generations. Ink4a/Arf null mice in a C57/B16 background were obtained from the National Cancer Institute Mouse Models of Human Cancer Consortium (Strain Number 01XB2). Genotyping was performed via PCR using tail-DNA.

Treatments

Colitis was induced in 17 p16-null Min mice by providing mice with drinking water containing 4% dextran sulfate sodium (DSS, molecular weight range 36,000–50,000, MPBio, Solon, OH) at 5 weeks of age. DSS was administered in two cycles, with each cycle consisting of 3 days of DSS and 11 days of untreated water. SNS-032 (kindly provided by Sunesis Pharmaceuticals Inc., San Francisco, CA) was administered by intraperitoneal (IP) injection 2x/wk at 30 mg/kg in 2.1 mM tartaric acid/0.9% sodium chloride, pH 4.2 during weeks without DSS. Mice were sacrificed at 12 weeks or when they approached a moribund state. To measure acute effects of SNS-032, mice received one week of DSS treatment followed by two injections of SNS-032 during the next week. Mice were sacrificed 5–6h after the last SNS-032 injection. Bromodeoxyuridine (BrdU; 100μL of a 10mg/ml solution; Sigma-Aldrich, St. Louis, MO) was injected IP 4h before euthanasia. 14 Ink4a/Arf-null Min mice were treated the same way except that DSS dose was reduced to 3% for 11 mice and SNS-032 dosing was increased to 3x/wk in all. Throughout the study, mice were monitored for diarrhea, gross rectal bleeding, and weight loss. All animal work was pre-approved by the Institutional Animal Care and Use Committee and met the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.

Histopathological analysis

Intestines from mice euthanized by carbon dioxide inhalation were resected, opened longitudinally under a dissecting microscope (Motic with Motic Images Plus 2.0.2 software, Ted Pella Inc., Pella, IA) and cleared of contents with a Kimwipe (Kimberly Clarke). An observer blinded to the treatment groups counted tumors and measured greatest tumor diameter, using an eyepiece reticle. Between 3 and 6 tumors were harvested per mouse. Sections were fixed in formalin, embedded in paraffin, sectioned, stained with hematoxylin, and subjected to immunohistochemistry. Standard procedures were used for antigen retrieval and tissue staining, as previously described (14, 15). Primary antibodies used were directed against BrdU (Becton Dickinson #555627, 1:100), cleaved/activated Caspase3 (Asp 175, Cell Signaling #9661, 1:200), and phospho-Histone H3 (Cell Signaling #9701, 1:100). Secondary antibodies were biotinylated anti-mouse IgG (H+L) (1:200, Vector Labs #BA-2001) and biotinylated anti-rabbit IgG (H+L) (1:200, Vector Labs #BA-1000).

Tissues pieces were embedded with the lumen perpendicular to the bottom of the block, and only well-oriented tissue (with intact crypts reaching the lumen) were scored. Activated Caspase3 and phospho-Histone H3 staining in epithelial cells was quantitated by counting positively stained cells per 40x microscope field (Nikon Eclipse E800 Microscope with Nikon ACT-1C software). BrdU staining was quantitated by counting positive cells per total epithelial cell count in a 40x field and calculating the percent positive cells.

Statistical analysis

Total numbers of tumors or tumor burden were compared using a likelihood ratio test, where the numbers were assumed to be Poisson distributed, or a Wilcoxon two-sample test. A random effects model was used to compare tumor sizes in drug- or carrier-treated animals. The Wilcoxon test was also used for comparisons of BrdU, PH3, or aCasp3 staining.

Results

The model

The Min (Multiple intestinal neoplasia) line represents the best-studied mouse model of intestinal tumorigenesis (16). These mice are heterozygous for an inactivating mutation in the adenomatous polyposis coli (APC) tumor suppressor protein, the most common mutation in human colon tumors. Adenomas form throughout the small intestine (jejunum and ileum) and large intestine (colon). The functional similarity of this phenotype to the human genetic disease APC (or Familial adenomatous polyposis) is underscored by recent evidence that microadenomas form throughout the small intestine in the human disease (17). We combined the Min mutation with lesions in the Ink4a/Arf pathway, for their ability to augment colon tumorigenesis and mimic Ink4a/Arf inactivation in the human disease (5, 15, 18, 19). In addition, we entertained the possibility that tumorigenesis driven in part by Cdk deregulation might be particularly susceptible to Cdk-targeted therapy. We initiated colitis in these mice by administration of dextran sulfate sodium (DSS). This treatment is known to augment Min tumorigenesis (20). Moreover, human ulcerative colitis is strongly associated with p16 inactivation (6, 7) and colon tumorigenesis (2123). Therefore, although no mouse model is without caveats, this combination of predisposing factors mirrors high-risk states for colon neoplasia in humans.

Reduced tumor burden in p16-null Min mice treated with SNS-032

Carrier or SNS-032 was administered to p16-null (24) Min mice by IP injection at doses shown to be effective in other experimental settings (11) (Sunesis company data). DSS was administered on weeks 5 and 7 (Fig 1). Drug or carrier was administered on weeks 6, 8, 9, and 10. Mice were euthanized on week 12. By this time point Min tumors are readily recognized by examination of dissected intestines under a dissecting microscope but there is little disease-related morbidity or mortality (15, 20). Colon tumor number and maximum diameter were scored by an observer blinded to the treatment groups and used to calculate tumor burden (total tumor area).

Fig 1
Experimental protocol

SNS-032 was well tolerated under these conditions, without obvious side effects. Drug-treated animals demonstrated 43% of the tumors and 36% of the tumor burden of carrier-treated mice (Fig 2, P < 0.003 and 0.001, respectively). Although death was not a designed endpoint in this study, 2 carrier-treated mice died during DSS treatment and one during the month before scheduled sacrifice, accounting for the lower number of carrier-treated mice scored. These results provide evidence for chemoprevention of colon tumorigenesis by SNS-032 in a model of colon tumorigenesis in situ.

Fig 2
SNS-032 reduced colon tumor number and burden in p16-null Min mice

Reduced tumor burden in Ink4a/Arf-null Min mice treated with SNS-032

We then extended our studies to Ink4a/Arf-null mice, which are defective in both p16 and Arf (13). Simultaneous silencing of both overlapping genes at the Ink4a/Arf locus is seen in a substantial fraction of human colon tumors (25). Moreover, Ink4a/Arf-null Min mice demonstrate a modestly more aggressive tumor phenotype than the corresponding p16-null mice (15, 18). We found early in course of the experiments that the Ink4a/Arf-null Min mice did not tolerate the DSS regimen used in p16-null mice, with several (both carrier and drug-treated) demonstrating major weight loss or death. We therefore reduced the concentration of DSS in the drinking water from 4% to 3%. No animal experienced major weight loss or overt illness on the new regimen. Because there were no significant side effects of SNS-032 when administered twice a week in p16-null mice, we increased the dosing frequency to 3x/week, with the goal of optimizing drug benefit. Thus, the experiments in Ink4a/Arf-null Min mice were intended to best test the efficacy of SNS-032 in this second genetic background, not to compare drug response between the respective Ink4a/Arf genotypes. We also extended our tumor analysis to the small intestine, which is largely unaffected by DSS treatment. Only the distal small intestine shows a modest increase in inflammation and Min tumorigenesis (26, 27).

SNS-032 reduced the number of intestinal tumors in Ink4a/Arf-null Min mice to 25% of that in carrier-treated mice (Fig 3A, P < 0.001). Tumors in drug-treated mice were also smaller on average (61% the size of those in carrier-treated mice, reaching significance in the distal ileum (P < 0.001), where tumor number was greatest). As a result the intestinal tumor burden was 16% of that in carrier-treated mice (Fig 3B, P< 0.0001). The degree of tumor reduction is on par with some of the strongest reported in intestinal tumor chemoprevention studies (1, 3, 2831). The drug effect was in fact strongest in the small intestine (Fig 3B), with each small intestine segment (jejunum, proximal ileum, and distal ileum) as well as colon showing a significant reduction in tumor burden (Fig 3B, P < 0.001 for each segment).

Fig 3
SNS-032 reduced intestinal tumor number and burden in Ink4a/Arf-null Min mice

Drug treatment was again well tolerated in the Ink4a/Arf-null Min DSS-treated mice, with all treated mice maintaining their weight (data not shown) and appearing generally healthy. At sacrifice, two drug-treated mice were noted to have pale liver lesions. Histological analysis demonstrated pockets of polymorphonuclear leukocytes and necrosis. It is unclear whether this pathology was related to the genetic background, the DSS treatment, the drug, or possibly infection arising from repeated IP injection. Similar lesions have not been noted with SNS-032 in other reported mouse or human trials ((11, 12, 32), Sunesis company data).

Cell cycle inhibition and apoptosis mediated by SNS-032

Min mouse intestinal tissues were examined for acute effects of SNS-032. In vitro studies with SNS-032 have shown accumulation of cells in G2/M phase and apoptosis (11). The G2/M accumulation is consistent with inhibition of Cdk2, based on evidence that G2 is the cell cycle phase most sensitive to Cdk2 inhibition (33). Cdks 7 and 9 appear to foster transcription of short-lived proteins such as the anti-apoptotic proteins Mcl-1 and XIAP. SNS-032 may induce apoptosis in part through such targets (11). Cdk2 inhibition might also contribute to apoptotic effects. For example, administration of Cdk2 antagonist peptides (34) and sustained induction of a Cdk2-dominant negative mutant (33) can promote apoptosis in cultured tumor cells. We sacrificed p16-null and Ink4a/Arf-null Min animals, respectively, 6h after the third dose of carrier or SNS-032 and 4h after administration of bromodeoxyuridine (BrdU). DNA synthesis, assayed by BrdU incorporation, was modestly but statistically significantly reduced by treatment with the drug (Figs 4A, ,5).5). However, a distinct reduction in mitotic index was confirmed by staining for phosphorylated histone H3 (PH3; Figs 4A, ,5).5). A marked increase in apoptosis, assayed by activated caspase 3 (aCasp3), was also noted (Figs 4A, ,5).5). Similar results were seen in Ink4a/Arf-wild type Min mice (data not shown).

Fig 4
Cell cycle inhibition and apoptosis mediated by SNS-032
Fig 5
Quantitation of cell cycle inhibition and apoptosis mediated by SNS-032 in p16-null and Ink4a/Arf-null jejunum (grey bars) and colon (black bars) in Min mice

We then extended these studies to Ink4a/Arf-null Min tumors from SNS-032 and carrier-treated mice. Reduced BrdU and PH3 and increased aCasp3 staining were readily demonstrated in these tissues (Figs 4B, ,6;6; data not shown). Similar results were obtained in tumor tissues from Ink4a/Arf-wild type Min mice (data not shown). These findings validate in intestinal tissue in situ biological effects of SNS-032 seen in vitro and in xenografts, and are consistent with inhibition of the identified targets of the drug.

Fig 6
Cell cycle inhibition and apoptosis mediated by SNS-032 in Min intestinal tumors

Discussion

We found that SNS-032 strongly reduced tumor burden in highly tumor prone mouse models of intestinal tumorigenesis. The lower mitotic index and increased apoptosis observed in tumor epithelial cells are consistent with inhibition of the known drug targets Cdks 2, 7, and 9. These results suggest efficacy of pharmacological Cdk inhibition for chemoprevention of intestinal tumorigenesis. The potent reduction of tumor burden observed in small intestine of Ink4a/Arf-null mice suggests that suppression of local inflammation is unlikely to be the principal mechanism of drug action. Inflammation is largely confined to the colon in DSS-treated mice (20, 27). To our knowledge, this is the first evidence for efficacy of SNS-032 or other small molecule Cdk inhibitors against intestinal tumors arising in situ. In situ models allow drug testing in immunocompetent animals, against the diversity of naturally arising tumors, and in native tumor microenvironments. Furthermore, drug efficacy can be tested in specific settings of tumor predisposition (e.g. colitis), specific genotypes generated through transgenic methods, and/or tumors generated by random mutagenesis, such as with azoxymethane (35).

The high incidence and prevalence of CRC in the general population, combined with its still substantial mortality and well-defined high-risk states, makes this disease particularly attractive for chemoprevention strategies. Most such efforts thus far have focused on COX-2 and other pathways involved in inflammation. Cdks have generally been viewed as potential targets in cancer chemotherapy but not in chemoprevention. One reason for this is that Cdks are involved in normal cell proliferation, which is required prominently for homeostasis in the bone marrow and intestinal epithelium. Thus, the `chemopreventive window', analogous to the `therapeutic window', for agents that target Cdks has been a concern. Indeed, we observed drug-mediated inhibition of proliferation and increased cell death of non-neoplastic intestinal epithelium. However, drug treatment was overall well tolerated. Some mice manifested diarrhea during the DSS treatment phase, but no diarrhea was noted during treatment with SNS-032. We did not assay hematopoietic parameters, but clinical signs of anemia (white paws, pale intestines, lethargy) were mild as a whole and not increased in the drug-treated group. Further work will be required to assess whether or not the occurrence of pockets of hepatic inflammation and necrosis in two Ink4/Arf-null:Min DSS-treated mice was drug-related. Similar hepatic lesions have not been reported in other pre-clinical models or clinical trials ((11, 12, 32); Sunesis company literature). Although SNS-032 has not been developed as an oral agent, humans have been given single oral doses in pilot studies (12). Bioavailability was between 4 and 33%, suggesting some potential for this route of administration. Our results establish the principle that chemoprevention with a Cdk inhibitor can be effective against intestinal tumorigenesis.

Some recent chemoprevention studies have combined agents, to achieve greater efficacy while minimizing side effects. The combination of difluoromethylornithine and sulindac has demonstrated impressive efficacy in secondary prevention of colon adenomas (36). Nonetheless, this strategy has not yet entered routine clinical use and concerns remain. Chemoprevention was incomplete, accompanied by measurable hearing loss in some patients, and may or may not translate to other high-risk groups. Cdk inhibition might eventually be considered for combination chemoprevention in high-risk groups, if buttressed by additional pre-clinical studies.

Our findings also support continued evaluation of SNS-032 in cancer therapy. Although early results have not been particularly promising (12), the regimens used have not always been pushed to maximum tolerated doses, have generally been quite different than the one used here, and have achieved some efficacy in hematopoietic malignancies (11). For example, some human trials have used intravenous infusion once a week or once every 3 weeks, rather than the 2–3x/wk treatment regimen in this study (12). The pre-clinical model used here presents an opportunity to more systematically test different regimens and the susceptibility of different tumor genotypes.

Acknowledgements

This work was supported by NIH R01 grant #DK64758 (to G.H.E.) and NCI Core grants to the FCCC Histopathology and Animal Care facilities (grant #P30 CA006927). We are grateful to Harry Cooper for pathological analyses and Sam Litwin for statistical analysis.

Grant support: NIH R01 DK64758

References

1. Clapper ML, Chang WC, Meropol NJ. Chemoprevention of colorectal cancer. Current opinion in oncology. 2001;13(4):307–13. [PubMed]
2. Gatof D, Ahnen D. Primary prevention of colorectal cancer: diet and drugs. Gastroenterol Clin North Am. 2002;31(2):587–623. xi. [PubMed]
3. Tuma R. Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. J Natl Cancer Inst. 2008;100(11):764–6. [PubMed]
4. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Can Res. 1998;72:141–96. [PubMed]
5. Herman JG. p16(INK4): involvement early and often in gastrointestinal malignancies. Gastroenterology. 1999;116(2):483–5. [PubMed]
6. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 1998;58(17):3942–5. [PubMed]
7. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007;132(4):1254–60. [PubMed]
8. Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res. 2004;10(12 Pt 2):4270s–5s. [PubMed]
9. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770–83. [PubMed]
10. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int J Cancer. 2002;102(5):463–8. [PubMed]
11. Conroy A, Stockett DE, Walker D, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 [PubMed]
12. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investigational new drugs. 2008;26(1):59–65. [PubMed]
13. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27–37. [PubMed]
14. Dai CY, Furth EE, Mick R, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology. 2000;119(4):929–42. [PubMed]
15. Gibson SL, Dai CY, Lee H-W, et al. Inhibition of colon tumor progression by the Ink4a/Arf locus. Cancer Research. 2003;63(4):742–6. [PubMed]
16. Luongo C, Moser AR, Gledhill S, Dove WF. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res. 1994;54(22):5947–52. [PubMed]
17. Preston SL, Leedham SJ, Oukrif D, et al. The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol. 2008;214(3):294–301. [PubMed]
18. Gibson SL, Boquoi A, Chen T, Sharpless NE, Brensinger C, Enders GH. p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors. Cancer Biol Ther. 2005;4(12):1389–94. [PMC free article] [PubMed]
19. Herman JG, Merlo A, Lapidus RG, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–30. [PubMed]
20. Cooper HS, Everley L, Chang WC, et al. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology. 2001;121(6):1407–16. [PubMed]
21. Jain SK, Peppercorn MA. Digestive diseases. 4–5. Vol. 15. Basel, Switzerland: 1997. Inflammatory bowel disease and colon cancer: a review; pp. 243–52. [PubMed]
22. Ransohoff DF. Colon cancer in ulcerative colitis. Gastroenterology. 1988;94(4):1089–91. [PubMed]
23. Snapper SB, Syngal S, Friedman LS. Digestive diseases. 2. Vol. 16. Basel, Switzerland: 1998. Ulcerative colitis and colon cancer: more controversy than clarity; pp. 81–7. [PubMed]
24. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 2001;413(6851):86–91. [PubMed]
25. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 2000;60(1):129–33. [PubMed]
26. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98(3):694–702. [PubMed]
27. Tanaka T, Kohno H, Suzuki R, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer. 2006;118(1):25–34. [PubMed]
28. Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutrition and cancer. 2008;60(Suppl 1):30–5. [PubMed]
29. Sporn MB, Hong WK. Concomitant DFMO and sulindac chemoprevention of colorectal adenomas: a major clinical advance. Nature clinical practice. 2008 [PubMed]
30. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 2006;66(14):7370–7. [PubMed]
31. Yang W, Bancroft L, Liang J, Zhuang M, Augenlicht LH. p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res. 2005;65(20):9363–8. [PMC free article] [PubMed]
32. Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007;9(5):370–81. [PMC free article] [PubMed]
33. Hu B, Mitra J, Heuvel Svd, Enders G. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant negative mutant in human cells. Molecular and Cellular Biology. 2001;21(8):2755–66. [PMC free article] [PubMed]
34. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists [see comments] Proc Natl Acad Sci U S A. 1999;96(8):4325–9. [PubMed]
35. Vivona AA, Shpitz B, Medline A, et al. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis. 1993;14(9):1777–81. [PubMed]
36. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Cancer prevention research. 1. Vol. 1. Philadelphia, Pa: 2008. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial; pp. 32–8. [PMC free article] [PubMed]